Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

Elastin-based peptides may help reduce wrinkles and could potentially benefit the scalp. The conversation suggests using them with hyaluronic acid gel to improve scalp health and reduce hair fall.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.

Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.

Bald men in Mozambique are being targeted due to superstitions that their heads contain gold, leading to dangerous rituals. The conversation humorously discusses this belief and its implications.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Copper peptide topical is being discussed for hair health, with some users noting it may improve hair volume. There is uncertainty about its effectiveness against hair loss.

Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

The conversation discusses concerns about a receding hairline potentially due to increased DHT from creatine use, with suggestions to try Rogaine. The user plans to seek a professional opinion and notes a family history of early baldness.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The conversation discusses purchasing finasteride tablets at a low cost in India, with users recommending reputable brands like Cipla and Intas over Zeelab due to quality concerns. Alternatives like MedPlus and Davaindia are suggested, and users share experiences with various brands, emphasizing the importance of quality over price.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

Minoxidil is commonly used for male pattern baldness, but Procapil is considered to have fewer side effects and be more effective. The user seeks information or experiences regarding Procapil.

A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.